Kato, Masaki http://orcid.org/0000-0001-6727-7272
Hori, Hikaru
Inoue, Takeshi
Iga, Junichi http://orcid.org/0000-0003-4409-3096
Iwata, Masaaki http://orcid.org/0000-0002-6143-0181
Inagaki, Takahiko
Shinohara, Kiyomi
Imai, Hissei
Murata, Atsunobu
Mishima, Kazuo
Tajika, Aran
Funding for this research was provided by:
Health and Labor Science Research Grants
Article History
Received: 30 March 2020
Revised: 3 July 2020
Accepted: 8 July 2020
First Online: 23 July 2020
Compliance with ethical standards
:
: The authors have declared that there are no conflicts of interest in relation to the subject of this study. We have had the following interests for the past 3 years. MK has received grant funding from the Japan Society for the Promotion of Science, SENSHIN Medical Research Foundation and Japan Research Foundation for Clinical Pharmacology, and speaker’s honoraria from Sumitomo Dainippon Pharma, Otsuka, Meiji-Seika Pharma, Eli Lilly, MSD K.K., GlaxoSmithKline, Pfizer, Janssen Pharmaceutical, Shionogi, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical, Lundbeck and Ono Pharmaceutical. Dr. Hori has received grant funding from Ministry of Education, Culture, Sports, Science and Technology Japan and UOEH Research Grant for Promotion of Occupational Health and speaker’s honoraria from Sumitomo Dainippon Pharma, Otsuka, Meiji-Seika Pharma, Eli Lilly, MSD K.K., Pfizer, Janssen Pharmaceutical, Shionogi, Takeda Pharmaceutical and Lundbeck. Dr. Inoue has received speaker’s honoraria from Mochida Pharmaceutical, Takeda Pharmaceutical, Eli Lilly, Janssen Pharmaceutical, MSD, Taisho Toyama Pharmaceutical, Yoshitomiyakuhin, and Daiichi Sankyo; grants from Shionogi, Astellas, Tsumura, and Eisai; grants and speaker’s honoraria from Otsuka Pharmaceutical, Dainippon Sumitomo Pharma, Mitsubishi Tanabe Pharma, Kyowa Pharmaceutical Industry, Pfizer, Novartis Pharma, and Meiji Seika Pharma; and is a member of the advisory boards of Pfizer, Novartis Pharma, and Mitsubishi Tanabe Pharma. Dr. Tajika received the lecture fee from Mitsubishi-Tanabe, Otsuka and Sumitomo Dainippon Pharma. Dr. Inagaki was employed through an endowed chair sponsored by the Government of Shiga Prefecture, Japan, from 2010 to 2016, has received grant funding from National Mutual Insurance Federation of Agricultural Cooperatives, Shionogi & Co., Ltd, Otsuka Pharmaceutical Co., Ltd, Shiga University of Medical Science and The Shiga Medical Science Association for International Cooperation and speaker’s honoraria from Japan Laim Corporation, Otsuka Pharmaceutical Co.,Ltd and Yoshitomiyakuhin Corporation. Dr. Iga has received grant funding from the Japan Society for the Promotion of Science and speaker’s honoraria from Sumitomo Dainippon Pharma, Otsuka, Meiji-Seika Pharma, Eli Lilly, MSD K.K., Novartis Pharma K.K., Sanofi K.K., Mochida Pharmaceutical, Takeda Pharmaceutical, Yoshitomiyakuhin, Eisai, Mylan, Sawai Pharmaceutical, Kyowa pharmaceutical industry, and Ono Pharmaceutical. Dr. Iwata has received grant funding from Japan Society for the Promotion Science, SENSHIN Medical Research Foundation, Japan Agency for Medical Research and Development and Osaka Gas, and speaker’s honoraria from Sumitomo Dainippon Pharma, Otsuka, Meiji-Seika Pharma, Eli Lilly, MSD K.K., Pfizer, Janssen Pharmaceutical and Mochida Pharmaceutical. Dr. Imai received the lecture fee from Tanabe-Mitsubishi pharma and Kyowa pharmaceutical industry outside the submitted work. Dr, Mishima has received research support from the Japanese Ministry of Health, Labor and Welfare (H29-Seishin-Ippan-001, 19GC1012); the Japanese Ministry of Education, Science, and Technology; and the National. Center of Neurology and Psychiatry Intramural Research Grant for Neurological and Psychiatric Disorders, and also collaborative research fund with Taisho Pharmaceutical Co., Ltd., speaker’s honoraria from Eisai Co., Ltd., MSD Inc., Takeda Pharmaceutical Co., Ltd., Astellas Pharma Inc., and Janssen Pharmaceutical along with research grants from Eisai Co., Ltd., Nobelpharma Co., Ltd., and Takeda Pharmaceutical Co., Ltd.